Condition: Relapsed B-cell Acute Lymphoblastic Leukemia · Refractory B-cell Acute Lymphoblastic Leukemia · Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd
This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
This description comes directly from the study's public registry record.
Xiaofan Zhu · 022-23909137 · xfzhu@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Hematology Hospital of the Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06179524